|
|
Blood, 15 May 2007, Vol. 109, No. 10, pp. 4158-4163.
Prepublished online as a Blood First Edition Paper on January 30, 2007; DOI 10.1182/blood-2006-07-035725.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
Pierre Fenaux1,
Azra Raza2,
Ghulam J. Mufti3,
Carlo Aul4,
Ulrich Germing5,
Hagop Kantarjian6,
Larry Cripe7,
René Kerstens8,
Peter De Porre8, and
Razelle Kurzrock6
1 Hôpital Avicenne, Paris, France;
2 Rush Cancer Institute, Chicago, IL;
3 Kings College, London, United Kingdom;
4 St Johannes Hospital, Duisburg, Germany;
5 Heinrich Heine University, Düsseldorf, Germany;
6 University of Texas M. D. Anderson Cancer Center, Houston, TX;
7 Indiana University Cancer Center, Indianapolis, IN;
8 Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium
This multicenter phase 2 study evaluated the use of tipifarnib (R115777) in patients with poor-risk myelodysplastic syndrome (MDS; French-American-British classification). Patients (n = 82) received tipifarnib 300 mg orally twice daily for the first 21 days of each 28-day cycle. Twenty-six patients (32%) responded to tipifarnib: 12 (15%) complete responses (CRs) and 14 (17%) hematologic improvements; 37 patients (45%) had stable disease (modified International Working Group criteria, 2006). Among the 12 CRs, the median response duration was 11.5 months (range, 2.0-21.9 months), the median time to progression was 12.4 months (range, 3.9-23.8 months), and 7 were still alive at time of analysis (all > 3 years). Median overall survival was 11.7 months (95% CI, 9.4-15.0). Grade 3-4 neutropenia (18%) and thrombocytopenia (32%) were the most common treatment-related adverse events; severe nonhematologic adverse events were rarely reported. In this study, durable responses and acceptable side effects were observed. Tipifarnib is an active agent for the treatment of patients with intermediate- to high-risk MDS.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J.-L. Harousseau, G. Martinelli, W. W. Jedrzejczak, J. M. Brandwein, D. Bordessoule, T. Masszi, G. J. Ossenkoppele, J. A. Alexeeva, G. Beutel, J. Maertens, et al.
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Blood,
August 6, 2009;
114(6):
1166 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, K. Flatten, E. J. Feldman, J. M. Greer, D. A. Loegering, R. M. Ricklis, L. E. Morris, E. Ritchie, B. D. Smith, V. Ironside, et al.
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
Blood,
May 14, 2009;
113(20):
4841 - 4852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Karp, B. D. Smith, I. Gojo, J. E. Lancet, J. Greer, M. Klein, L. Morris, M. J. Levis, S. D. Gore, J. J. Wright, et al.
Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features
Clin. Cancer Res.,
May 15, 2008;
14(10):
3077 - 3082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hong, L. Ye, R. Gagel, L. Chintala, A. K. El Naggar, J. Wright, and R. Kurzrock
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib
Mol. Cancer Ther.,
May 1, 2008;
7(5):
1001 - 1006.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kurzrock, H. M. Kantarjian, M. A. Blascovich, C. Bucher, S. Verstovsek, J. J. Wright, S. R. Pilat, J. E. Cortes, E. H. Estey, F. J. Giles, et al.
Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome
Clin. Cancer Res.,
January 15, 2008;
14(2):
509 - 514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
